A Prospective Study of Urinary Prostaglandin E2 Metabolite, Helicobacter pylori Antibodies, and Gastric Cancer Risk.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 28402440)

Published in Clin Infect Dis on May 15, 2017

Authors

Tianyi Wang1,2, Hui Cai2, Wei Zheng2, Angelika Michel3, Michael Pawlita3, Ginger Milne4, Yong-Bing Xiang5, Yu-Tang Gao5, Hong-Lan Li5, Nathaniel Rothman6, Qing Lan6, Xiao-Ou Shu2, Meira Epplein2

Author Affiliations

1: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Cancer Epidemiology, Peking University Cancer Hospital and Institute, Peking University Health Science Center, Beijing, China.
2: Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center and Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
3: Division of Molecular Diagnostics of Oncogenic Infections, Research Program in Infection, Inflammation, and Cancer, German Cancer Research Center, Heidelberg, Germany.
4: Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
5: Department of Epidemiology, Shanghai Cancer Institute, China; and.
6: Division of Cancer Epidemiology and Genetics, Occupational and Environmental Epidemiology Branch, National Cancer Institute, National Institutes of Health, Rockville, Maryland.

Articles cited by this

Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem (2000) 8.86

The Shanghai Women's Health Study: rationale, study design, and baseline characteristics. Am J Epidemiol (2005) 6.44

Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer (2001) 4.62

Is obesity an inflammatory condition? Nutrition (2001) 4.25

Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem (2005) 4.18

Altered eicosanoid levels in human colon cancer. J Lab Clin Med (1993) 3.32

COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol (2005) 3.15

Aging and proinflammatory cytokines. Curr Opin Hematol (2001) 3.05

Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res (1997) 2.99

Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell (2003) 2.71

Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem (2004) 2.24

Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-alpha and phorbol ester. J Clin Invest (1994) 1.89

On the metabolism of prostaglandins E 1 and E 2 in man. J Biol Chem (1971) 1.71

Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk. J Clin Oncol (2006) 1.62

Inverse correlation between serum PGE2 and T classification in head and neck cancer. Head Neck (2007) 1.58

Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci U S A (2006) 1.52

Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol (2000) 1.50

Helicobacter pylori multiplex serology. Helicobacter (2009) 1.29

Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection. Am J Gastroenterol (1999) 1.28

Aspirin and risk for gastric cancer: a population-based case-control study in Sweden. Br J Cancer (2001) 1.26

Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res (2005) 1.26

Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol (2004) 1.25

Urinary prostaglandin E2 metabolite and gastric cancer risk in the Shanghai women's health study. Cancer Epidemiol Biomarkers Prev (2009) 1.23

Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer. Cancer Prev Res (Phila) (2013) 1.17

Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res (1988) 1.13

Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers. Clin Cancer Res (2005) 1.10

Alcohol consumption, smoking and risk of gastric cancer: case-control study from Moscow, Russia. Cancer Causes Control (2000) 1.08

Aspirin use and the risk of gastric cancer: a meta-analysis. Dig Dis Sci (2009) 1.08

Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut (2011) 1.02

Cohort Profile: The Shanghai Men's Health Study. Int J Epidemiol (2015) 1.01

Tobacco, alcohol and the risk of gastric cancer. A population-based case-control study in Sweden. Int J Cancer (1994) 0.99

Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and alpha-difluoromethylornithine on tumorigenesis in a rat surgical model. Carcinogenesis (2002) 0.96

Five-lipoxygenase pathway of arachidonic acid metabolism in carcino-genesis and cancer chemoprevention. Curr Cancer Drug Targets (2006) 0.95

Helicobacter pylori blood biomarker for gastric cancer risk in East Asia. Int J Epidemiol (2016) 0.82

Urinary prostaglandin E2 metabolite and breast cancer risk. Cancer Epidemiol Biomarkers Prev (2014) 0.81

Helicobacter pylori, cyclooxygenase-2 and evolution of gastric lesions: results from an intervention trial in China. Carcinogenesis (2015) 0.79

Urinary prostaglandin E2 metabolite and pancreatic cancer risk: case-control study in urban Shanghai. PLoS One (2015) 0.77

Urinary Metabolites of Prostanoids and Risk of Recurrent Colorectal Adenomas in the Aspirin/Folate Polyp Prevention Study (AFPPS). Cancer Prev Res (Phila) (2015) 0.77